PreciseBreast™ has the potential to
deliver significant savings to payers and patients, while providing
a more accurate measure of clinical risk; ultimately supporting
treatment and management decisions for all patients with invasive
breast cancer
NEW
YORK, July 23, 2024 /PRNewswire/ -- PreciseDx®,
a leading innovator in oncology diagnostics leveraging Artificial
Intelligence (AI) for revolutionary, morphology-driven disease
analysis, today announced that its economic impact study for
PreciseBreast™ risk assessment has been published in the July issue
of the Journal of Medical Economics.
The study calculated the cost impact of using
PreciseBreast™(also referred to as PDxBr), an AI histopathology
platform that predicts the 6-year risk of recurrence in early-stage
invasive breast cancer (IBC) patients to aid in the treatment
decision process (i.e. use of chemotherapy). The study compared the
costs of treatment guided by standard of care (SOC) risk assessment
(i.e., 21 gene expression test and histopathology assessment)
versus PreciseBreast™ in conjunction with SOC. A hypothetical
cohort of one million U.S. women with early-stage invasive breast
cancer was used for the study.
Cost impact considered the cost of testing, adjuvant therapy,
recurrence, adverse events, surveillance, and end-of-life care from
a commercial payer perspective. The findings are compelling: when
used as part of a recurrence risk evaluation in a hypothetical
cohort of one million female members, use of PreciseBreast™
resulted in cost savings of $4M in
year one compared to the current standard of care alone. Over 6
years, the savings increased to $12.5M. The per-treated patient costs calculated
in year one were $19.5K for
traditional standard of care and $16.9K for PreciseBreast™.
"We are very pleased with these findings and the potential
impact on both healthcare costs and patient care," said
Michael J. Donovan, Co-founder and
Chief Medical Officer of PreciseDx. "With PreciseBreast, we are
potentially shielding many low-risk patients from the unnecessary
toxicity of chemotherapy, while also providing significant savings
to payers. In addition, PreciseBreast is a digital prognostic test
which relies on the patient's own readily available diagnostic
tissue specimen from the pathology lab, ensuring accessibility to
oncologists and pathologists regardless of geographic
location."
PreciseBreast™ uses Artificial Intelligence (AI) and Machine
Learning (ML) combined with its Morphology Feature Array (MFA®) to
analyze invasive breast cancer histology images with the purpose of
enhancing and improving the traditional grading approach.
PreciseBreast™ is an in vitro prognostic test that predicts
breast cancer recurrence for patients diagnosed with early-stage
IBC.
"Our validated AI-powered MFA platform (using digital whole
slide image analysis) is changing how we can assess and analyze
patient data to positively impact healthcare," said Ted Diehl, Vice President of Commercial
Development at PreciseDx. "For breast cancer patients and their
physicians, PreciseBreast is providing accurate and objective risk
stratification within 48 hours at 20% the cost of gene expression
testing. PreciseBreast provides an accurate and effective
sequence to gene expression testing and was established to
enhance current histopathology assessment that is accessible,
affordable, and easily available."
About PreciseDx®
PreciseDx® is innovating oncology diagnostics, leveraging
Artificial Intelligence (AI) for revolutionary, morphology-driven
disease analysis. Combining AI with our patented Morphology Feature
Array® (MFA), PreciseDx provides access to unmatched disease
insights and accurate, actionable intelligence for more
comprehensive decision-making throughout the cancer care continuum.
To learn more about PreciseDx, visit https://precisedx.ai/
About PreciseBreast™
PreciseBreast™ is an early-stage
invasive breast cancer risk assessment, independent of HER2, and
hormone receptor status. The AI-powered test utilizes standard
H&E pathology slide images. Leveraging millions of data points,
PreciseBreast™ analyzes, correlates, and quantifies those critical
features that predict breast cancer recurrence and delivers a Risk
of Recurrence Score. The test meets the rigorous Clinical
Laboratory Improvement Amendments (CLIA) standards and has passed
the Clinical Laboratory Evaluation Program (CLEP) Assay Validation
Review by the New York State
Department of Health (NYSDOH). PDxBr will be available worldwide
under the brand name of PreciseBreast™. For more information,
please contact precisebreast@precisedx.ai.
For media inquiries or further information, please contact:
Hannah Davis
860-707-9461
Hannah@0to5.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/precisedx-announces-publication-of-its-cost-impact-study-payer-impact-of-precisebreastpdxbr-to-identify-breast-cancer-recurrence-in-the-journal-of-medical-economics-302203518.html
SOURCE PreciseDx